Provided by Tiger Trade Technology Pte. Ltd.

Xeris Pharmaceuticals Inc

8.74
+0.04000.46%
Post-market: 8.740.00000.00%16:10 EDT
Volume:870.74K
Turnover:7.59M
Market Cap:1.59B
PE:-85.68
High:8.80
Open:8.66
Low:8.54
Close:8.70
52wk High:10.08
52wk Low:5.25
Shares:182.32M
Float Shares:172.57M
Volume Ratio:0.47
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1020
EPS(LYR):0.0032
ROE:-617.16%
ROA:6.13%
PB:-163.70
PE(LYR):2,725.29

Loading ...

A Look At Xeris Biopharma Holdings (XERS) Valuation After Its Profit Turnaround And Guidance Hike

Simply Wall St.
·
May 11

Oppenheimer Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)

TIPRANKS
·
May 08

Stock Track | Xeris Pharmaceuticals Soars 5.02% in Pre-market on Strong Q1 Results and Raised Guidance

Stock Track
·
May 07

GUIDANCE: (XERS) Xeris Biopharma Expects 2026 Revenue Range $380M - $390M, vs. FactSet Est of $383.3M

MT Newswires Live
·
May 07

Earnings Flash (XERS) Xeris Biopharma Holdings Posts Q1 EPS $0.01, vs. FactSet Est of $0.01 Loss per Share

MT Newswires Live
·
May 07

Xeris Biopharma Holdings Q1 EPS $0.01 Beats $(0.00) Estimate, Sales $83.127M Beat $79.992M Estimate

Benzinga Earnings
·
May 07

BRIEF-Xeris Biopharma Q1 Net Income USD 2.234 Million

Reuters
·
May 07

Xeris Biopharma Holdings Inc - Tightens FY2026 Total Revenue Guidance to $380 Mln-$390 Mln

THOMSON REUTERS
·
May 07

Xeris Biopharma Q1 EPS USD 0.01

THOMSON REUTERS
·
May 07

Xeris Biopharma CLO Beth Hecht disposes 16,667 shares for $103,804.31

Reuters
·
May 02

Earning Preview: Xeris Pharmaceuticals Inc revenue is expected to increase by 38.85%, and institutional views are cautiously optimistic

Earnings Agent
·
Apr 30

Xeris Biopharma to report first-quarter results, host conference call

Reuters
·
Apr 23

Xeris Biopharma director Jeffrey Sherman to retire from board

Reuters
·
Apr 22

Record Profitability, 2026 Growth Outlook and Recorlev Patent Suit Might Change The Case For Investing In Xeris Biopharma Holdings (XERS)

Simply Wall St.
·
Apr 14

Xeris Biopharma Chief Legal Officer Beth Hecht sells under $1 million common shares

Reuters
·
Apr 04

Xeris grants 305,000 restricted stock units to 90 new employees under inducement plan

Reuters
·
Apr 04

Xeris Biopharma director James Brady disposes of USD 0.1 million common shares

Reuters
·
Apr 02

Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services

Reuters
·
Mar 23

Xeris Biopharma Chief Legal Officer and Corporate Secretary Beth Hecht Disposes of Common Shares

Reuters
·
Mar 05

Xeris Biopharma Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 03